SCHEMBL23779099

SCHEMBL23779099

O=C(Nc1cc2n(n1)CCN(C(=O)c1cc3ccccc3[nH]1)C2)C1CCN(C2CCOCC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ SYK P43405 2/20 0.45
▸ HDAC6 Q9UBN7 1/20 0.45
▸ HRH3 Q9Y5N1 2/20 0.43
▸ HRH4 Q9H3N8 5/20 0.42
▸ AKR1C3 P42330 7/20 0.40
▸ WNT1 P04628 1/20 0.40
▸ GSK3B P49841 1/20 0.40
▸ DYRK1A Q13627 1/20 0.40
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA7 P43166 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ NAMPT P43490 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23779083 0.94 HDAC6 (0.48) POLBSMN1; SMN2SYKHDAC6HRH3
SCHEMBL23779075 0.93 POLB (0.53) POLBSMN1; SMN2HDAC6HRH3HRH4
SCHEMBL23779102 0.89 POLB (0.48) POLBSMN1; SMN2HDAC6HRH3HRH4
SCHEMBL24319828 0.86 HRH4 (0.54) POLBSMN1; SMN2HDAC6HRH3HRH4
SCHEMBL23779096 0.85 HDAC6 (0.48) POLBSMN1; SMN2HDAC6HRH3HRH4
SCHEMBL23779127 0.85 AKR1C3 (0.49) POLBSMN1; SMN2HDAC6HRH3HRH4
SCHEMBL23779060 0.85 HRH4 (0.54) POLBSMN1; SMN2HDAC6HRH3HRH4
Hydrochloric Acid SCHEMBL23779057 0.85 HRH4 (0.53) POLBSMN1; SMN2HDAC6HRH3HRH4
SCHEMBL24320719 0.84 HDAC6 (0.50) POLBSMN1; SMN2HDAC6HRH3HRH4
SCHEMBL23779090 0.84 AKR1C3 (0.48) POLBSMN1; SMN2HDAC6HRH3HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220081444-A1 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AICURIS GMBH & CO. KG (DE) 2022-03-17 — — US disclosed
US-20220081444-A1 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AICURIS GMBH & CO. KG (DE) 2022-03-17 — — US disclosed
EP-3873910-A1 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AiCuris GmbH & Co. KG (DE) 2021-09-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220081444-A1 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) HCCS, CDK2, BRD4 POLB 536/4885SMN1; SMN2 4877/4885SYK 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback